Forget MannKind Corporation; Here Are 3 Better Biotech Stocks
Fits and starts in developing a revolutionary new inhaled insulin have meant that Al Mann’s MannKind has had more than its fair share of pops and drops over the past few years. MannKind won FDA approval for Afrezza last summer and announced its commercial launch earlier this month . The news has investors wondering if now is a good time […]
